Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug84 | AKS-452 Wiki | 0.71 |
drug369 | BCG-10 vaccine Wiki | 0.71 |
drug16 | 0.9% saline Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D000257 | Adenoviridae Infections NIH | 0.32 |
D003141 | Communicable Diseases NIH | 0.29 |
D007239 | Infection NIH | 0.17 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation
Description: Occurrence of SAEs following the first vaccination and throughout the study duration (Day 180).
Measure: Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability]. Time: 180 daysDescription: Local and systemic solicited AEs for 7 days following each vaccination. Unsolicited AEs for 28 days following each vaccination. Occurrence of AESIs following the first vaccination and throughout the study duration (Day 180).
Measure: Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability]. Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: SARS-CoV-2 antigen-specific antibody levels Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: The rate of participants seroconverting from negative to positive SARS-CoV-2 N Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Quantity of SARS-CoV-2 neutralizing antibodies Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Count of peripheral blood mononuclear cells (PBMCs) Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Quantity of seasonal coronavirus antigens Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time Time: 180 daysThe objective is to evaluate the safety and immunogenicity of AZD1222 given in combination with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of age.
Description: Incidence of local and systemic solicited AEs for 7 days post each dose Incidence of unsolicited AEs for 28 days post each dose Incidence of SAEs and AESIs to 28 days post second dose
Measure: Incidence of local and systemic solicited AEs for 7 days post each dose Incidence of unsolicited AEs for 28 days post each dose Incidence of SAEs and AESIs to 28 days post second dose Time: 180 daysDescription: Safety
Measure: Incidence of SAEs and AE of Special Interest until study end Time: 180 daysDescription: immunogenicity
Measure: SARS-CoV-2 antigen-specific antibody levels Time: 57 daysDescription: immunogenicity
Measure: To assess antibody responses Time: Up to 180 daysDescription: immunogenicity
Measure: Quantity of SARS-CoV-2 neutralizing antibodies Time: Up to 180 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports